The Epipodophyllotoxin Derivatives VM-26 and VP-16-213, 1976–1979, a Review
- 1 January 1980
- book chapter
- Published by Springer Nature
- Vol. 74, 98-106
- https://doi.org/10.1007/978-3-642-81488-4_14
Abstract
The epipodophyllotoxin derivatives VM 26 and VP16-213 are currently entering phase III studies. The mechanism of their action is incompletely understood, but the greatest lethal effect is experienced in the late S and G2 phases. In transplanted tumors both drugs have shown marked schedule dependency and human studies also support this. As a single agent VP 16-213 is among the most active drugs in small-cell carcinoma of the lung. Significant clinical activity (> 20% response frequency) has been observed for both drugs in Hodgkin’s disease, non-Hodgkin lymphomas and possibly in other more rare tumors (monocytic leukemia, hepatoma and teratoma). Although further clinical studies of both drugs would be ideal, it seems possible at present to justify a discontinuation of VM-26 in order to concentrate the efforts on VP 16-213. Further studies are needed to define optimal dose and schedule and place in combination chemotherapy.Keywords
This publication has 13 references indexed in Scilit:
- Clinical trial of VP 16–213 (NSC 141540) I.V. Twice weekly in advanced neoplastic disease a study by the cancer and leukemia group BCancer, 1980
- VM26 (NSC-122819): A clinical study in advanced cancer of the lung and ovaryPublished by Elsevier ,1978
- Activity of the Epipodophyllotoxin VP-16 in the Treatment of Combination Chemotherapy-Resistant Non-Hodgkin LymphomaAmerican Journal of Hematology, 1978
- Treatment of small cell anaplastic carcinoma of the lung with the oral solution of VP-16-213 (NSC 141540, 4′-demethylepipodophyllotoxin 9-(4,6-0-ethylidene-β-D-glucopyranoside)Cancer, 1977
- VM 26 and VP 16–213: A comparative analysisCancer, 1977
- Effects of podophyllotoxin and VP-16-213 on microtubule assembly in vitro and nucleoside transport in HeLa cellsBiochemistry, 1976
- A clinical trial of the oral form of 4′-demethyl-epipodophyllotoxin-β-D ethylidene glucoside (NSC 141540) VP 16–213Cancer, 1975
- Two epipodophyllotoxin derivatives, VM 26 and VP 16213, in the treatment of leukemias, hematosarcomas, and lymphomasCancer, 1974
- Epipodophyllotoxin VP 16213 in Treatment of Acute Leukaemia--Haematosarcoma and Solid TumoursBMJ, 1973
- Clinical Screening of Epipodophyllotoxin VM26 in Malignant Lymphomas and Solid TumoursBMJ, 1972